Brownstone » Brownstone Journal » Pharma » Pfizer Lied to Us Again
Pfizer Lied to Us Again

Pfizer Lied to Us Again

SHARE | PRINT | EMAIL

There used to be a time where claims from pharmaceutical companies may have been treated with some degree of skepticism from major institutions and media outlets.

Yet in late 2020 and into 2021, suddenly skepticism turned to complete blind faith. But what changed? Why, political incentives, of course!

Initially, Covid vaccines produced by Pfizer were seen as dangerous and untested; they were considered a Trump vaccine that only idiots who were willing to risk their own health would take. However when the 2020 election had been officially decided, and Biden and his political allies represented the Covid vaccines as the pathway out of the pandemic, a moral choice that would help yourself and others, narratives and incentives changed dramatically.

Pfizer became a heroic symbol of virtue, and all questioning of Covid vaccines was grounds for immediate expulsion from polite society, regardless of the actual efficacy of Pfizer’s products.

Much of the blame for the vaccines’ underperformance could be placed on Pfizer itself; the company relentlessly promoted hopelessly inaccurate efficacy estimates and supported efforts to unnecessarily mandate mRNA shots. 

Sure enough, on the back of progressive orthodoxy, corporate and institutional incompetence and media activism, they proudly reported record revenues.

We all know how that turned out in 2022 and 2023. 

Skepticism towards Pfizer’s vaccine was obviously quite well warranted. And it turns out that now we, and of course, Pfizer’s chief promoters in the media and public health class should have been even more skeptical.

Stay Informed with Brownstone Institute

They weren’t.

Pfizer’s Claims On Covid Treatments Were Wildly Inaccurate

As the Covid vaccines failed spectacularly to stop the spread of infections and did nothing to lessen all-cause mortality or even decrease population level Covid-associated deaths in highly vaccinated countries, Pfizer saw another opportunity.

Sure, their signature product failed to perform as expected. So why not create another one as an antidote?

Enter Paxlovid. 

Paxlovid, an antiviral drug, was supposed to help individuals with symptomatic Covid, who’d already been infected, recover more quickly and lessen the risk of severe illness. Sounds great right? 

It would appear that it sure did to Anthony Fauci and the cadre of media-promoted “experts.” 

Fauci praised Paxlovid in 2022, after the mRNA vaccines and booster doses failed to prevent him from contracting Covid. Bizarrely, Fauci implied that the same Pfizer products that he demanded everyone take would not have been enough to keep him healthy, saying that he believed Paxlovid had kept him out of the hospital.

Never mind, of course, that Fauci had a “rebound” case of Covid-19 after taking Paxlovid and getting vaccinated and boosted. Acknowledging imperfections would undercut his desire to get everyone to take more of his preferred products. 

Paxlovid made headlines again later in 2022 as Rochelle Walensky also praised Pfizer’s efforts, despite once again testing positive for “rebound” Covid after Paxlovid treatments.

Even today, the CDC’s own website says Paxlovid is an “effective” treatment for those who’ve contracted the virus and want to avoid severe illness. 

There’s just one problem; it’s not true.

A newly released study on Paxlovid on randomized adults with symptomatic Covid; one subset was given Paxlovid (nirmatrelvir-ritonavir) or a placebo every 12 hours for five days, with the intent of determining how effective it was at “sustained alleviation” of Covid-19 symptoms.

In this phase 2–3 trial, we randomly assigned adults who had confirmed Covid-19 with symptom onset within the past 5 days in a 1:1 ratio to receive nirmatrelvir–ritonavir or placebo every 12 hours for 5 days. Patients who were fully vaccinated against Covid-19 and who had at least one risk factor for severe disease, as well as patients without such risk factors who had never been vaccinated against Covid-19 or had not been vaccinated within the previous year, were eligible for participation. Participants logged the presence and severity of prespecified Covid-19 signs and symptoms daily from day 1 through day 28. The primary end point was the time to sustained alleviation of all targeted Covid-19 signs and symptoms. Covid-19–related hospitalization and death from any cause were also assessed through day 28.

Spoiler alert: it wasn’t effective at all.

Their measured results revealed that there was effectively no difference whatsoever in the “sustained alleviation” of symptoms between Paxlovid and a placebo. Those taking Pfizer’s miracle antiviral treatment saw their “signs and symptoms” resolve after 12 days, while the placebo recipients took 13 days. 

The median time to sustained alleviation of all targeted signs and symptoms of Covid-19 was 12 days in the nirmatrelvir–ritonavir group and 13 days in the placebo group (P=0.60). Five participants (0.8%) in the nirmatrelvir–ritonavir group and 10 (1.6%) in the placebo group were hospitalized for Covid-19 or died from any cause (difference, −0.8 percentage points; 95% confidence interval, −2.0 to 0.4).

This is the product that to this day is relentlessly promoted by the CDC, the media, and politicians as an effective tool to reduce the severity of symptoms and the length of illness. And it was virtually meaningless. 

Even with regards to the most severe outcomes, hospitalization, and death, the difference was negligible. Confidence intervals for the difference in outcome even stretched to a positive relationship, meaning that it’s within the bounds of possibility that more people died or were hospitalized after taking Paxlovid than a placebo. 

Succinctly, the researchers confirmed in their summary that there was no difference between the two treatments.

The time to sustained alleviation of all signs and symptoms of Covid-19 did not differ significantly between participants who received nirmatrelvir–ritonavir and those who received placebo.

But who are these researchers, you might ask…surely they’re fringe scientists, desperate to undercut a big, bad pharmaceutical company, right? How else could their conclusions so thoroughly undermine Pfizer?

Let’s take a look at the disclosure to see who funded this study, designed the trial, conducted it, collected the data, and analyzed the results. Surely, that will reveal the nefarious intentions behind this dastardly attempt to cut at the heart of Pfizer’s miracle drug.

Pfizer was responsible for the trial design and conduct and for data collection, analysis, and interpretation. The first draft of the manuscript was written by medical writers (funded by Pfizer) under direction from the authors.

Oh. Oh no.

Pfizer created the trial, conducted it, collected the data, and analyzed it. And it found that Paxlovid made no difference to the resolution of symptoms or with keeping people alive or out of the hospital. That has to sting.

Even worse, Covid vaccination was once again proven to be almost entirely irrelevant where results were concerned. Results were the same between “high-risk subgroups,” meaning those who had been vaccinated but had an elevated risk for more serious symptoms, and those who had never been vaccinated or had received the last dose more than a year ago.

Similar results were observed in the high-risk subgroup (i.e., participants who had been vaccinated and had at least one risk factor for severe illness) and in the standard-risk subgroup (i.e., those who had no risk factors for severe illness and had never been vaccinated or had not been vaccinated within the previous 12 months).

So not only did Paxlovid not make a difference, but vaccination status AND Paxlovid wasn’t enough to create a sizable gap in outcomes between healthy, unvaccinated individuals.

But wait, there’s more. 

Viral load rebounds were also more common in the Paxlovid group, and symptom and viral load rebounds combined were more common among those taking Pfizer’s treatment. While percentages were generally low, other studies have pegged Paxlovid-associated rebound as occurring nearly one quarter of the time. 

So it’s not particularly effective at reducing symptoms or resolving them more quickly, doesn’t lead to statistically significant improvements in the most severe outcomes, and is more likely to result in a rebound case of the illness it’s supposed to be protecting you from.

Sounds exactly like the type of product that Fauci, Walensky, and the CDC would praise, doesn’t it?

Paxlovid is the entire Covid-pharmaceutical complex summarized perfectly. Created to solve a problem that was supposed to be fixed by another product…understudied, overhyped by the “experts,” and prematurely authorized by a desperate FDA…and ultimately shown to be mostly ineffective.

Once again, the actual science disproves The Science™. And once again, we’ll get no acknowledgement of it or apologies for the billions of taxpayer dollars wasted. Can’t wait to see what Pfizer does for an encore.

Republished from the author’s Substack



Published under a Creative Commons Attribution 4.0 International License
For reprints, please set the canonical link back to the original Brownstone Institute Article and Author.

Author

Donate Today

Your financial backing of Brownstone Institute goes to support writers, lawyers, scientists, economists, and other people of courage who have been professionally purged and displaced during the upheaval of our times. You can help get the truth out through their ongoing work.

Subscribe to Brownstone for More News

Stay Informed with Brownstone Institute